rawfin.tv
BioAge Labs Begins Phase 2 Trial for Cardiovascular Drug BGE-102
TechnologystocksAI Generated

BioAge Labs Begins Phase 2 Trial for Cardiovascular Drug BGE-102

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

BioAge Labs, in partnership with HitGen, has dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102. This novel oral NLRP3 inhibitor aims to reduce cardiovascular risk, marking a significant step in its clinical development.

BiotechnologyClinical TrialsCardiovascular HealthDrug Development

Related Articles

Nasdaq Drops Nearly 700 Points While Traders Assess History

Nasdaq Drops Nearly 700 Points While Traders Assess History

stocks
S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

stocks
China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks